Expertise in
36
conditions

Dr. Fasahat Hamzavi

Dermatology
Detroit, MI 
Expertise in
36
conditions
Detroit, MI 

Overview

Fasahat Hamzavi is a Dermatologist practicing medicine in Detroit, Michigan.

Dr. Hamzavi is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Liver Spots, Universal Acquired Melanosis, Actinic Keratosis, and Warts.

He is actively involved in clinical research, participating in 7 clinical trials.

Specialties

Dermatology

Licenses

Dermatology in MI

Hospital Affiliations

Mclaren Port Huron

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Detroit, MI 48201
Other Locations
43151 Dalcoma Dr # 1, Clinton Township, MI 48038
Detroit, MI 48201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Combination product
Study Phase: Phase 3
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
Enrollment Status: Completed
Publish Date: February 15, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials
Similar Doctors
Expertise in
12
conditions
Dr. David Ozog
Dermatology
Expertise in
12
conditions
Dr. David Ozog
Dermatology

Henry Ford Cancer-Detroit

2800 W Grand Blvd, 
Detroit, MI 
 (18.2 miles away)
888-777-4167
Languages Spoken:
English
See accepted insurances

David Ozog is a Dermatologist practicing medicine in Detroit, Michigan. Dr. Ozog is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Keloids, Muir-Torre Syndrome, Basal Cell Skin Cancer, and Bowen's Disease.

Expertise in
39
conditions
Dr. Johann Gudjonsson
Dermatology
Expertise in
39
conditions
Dr. Johann Gudjonsson
Dermatology
1500 E Medical Center Dr # 1910, 
Ann Arbor, MI 
 (44.1 miles away)
734-936-4054
Languages Spoken:
English
See accepted insurances

Johann Gudjonsson, MD, PhD is the Arthur C. Curtis Professor of Molecular Skin Immunology and the Frances and Kenneth Eisenberg Emerging Scholar of the Taubman Medical Research Institute. A graduate of the University of Iceland Medical School, he completed his internship and dermatology residency training at the University of Michigan. Dr. Gudjonsson has served on the faculty of the University of Michigan Department of Dermatology since 2008. He provides general medical dermatology patient care at the University of Michigan Taubman Center and maintains clinical and research interests in inflammatory and autoimmune disorders involving the skin.Dr. Gudjonsson came to the U-M in 2003 as part of an innovative research residency training program. Building upon investigative dermatology training completed in Iceland, Dr. Gudjonsson has been performing basic immunological and genetic work on psoriasis at the U-M. Dr. Gudjonsson's primary research focus is basic immunological and genetic research on psoriasis, with projects directed at improving the diagnosis and treatment of psoriasis. He received the 2007 Young Investigator Award from the American Academy of Dermatology, was named the 2018 Rising Star Lecturer for the Society for Investigative Dermatology and was recipient of the American Skin Association Research Achievement Award in Psoriasis in 2021. Dr. Gudjonsson's research has been supported by research awards from the National Institutes of Health (NIH), the American Skin Association, Dermatology Foundation, Doris Duke Foundation, among others. Dr. Gudjonsson is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Psoriasis, Darier Disease, Benign Chronic Pemphigus, Cutaneous Lupus Erythematosus (CLE), and Vitrectomy. Dr. Gudjonsson is board certified in Dermatology.

Expertise in
31
conditions
Dr. Iltefat Hamzavi
Dermatology
Expertise in
31
conditions
Dr. Iltefat Hamzavi
Dermatology
2305 Genoa Business Park Dr # 180, 
Brighton, MI 
 (40.1 miles away)
734-844-6400
Experience:
30+ years
Languages Spoken:
English
See accepted insurances

Iltefat Hamzavi is a Dermatologist practicing medicine in Brighton, Michigan. He has been practicing medicine for over 30 years. Dr. Hamzavi is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Vitiligo, Hypomelanotic Disorder, Hidradenitis Suppurativa, and Acne. Dr. Hamzavi is board certified in American Board Of Dermatology.

Frequently Asked Questions about Dr. Fasahat Hamzavi

How do I make an appointment with Dr. Fasahat Hamzavi?

You can book an appointment with Dr. Fasahat Hamzavi by calling their office at 734-495-1506. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Fasahat Hamzavi a top-rated expert for Liver Spots?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Fasahat Hamzavi is classified as an Distinguished expert for Liver Spots, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Fasahat Hamzavi specialize in?

While Dr. Fasahat Hamzavi is a Dermatology, they have specific expertise in Liver Spots, Universal Acquired Melanosis, and Actinic Keratosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Fasahat Hamzavi accept my insurance?

Dr. Fasahat Hamzavi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 734-495-1506 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hamzavi's expertise for a condition
ConditionClose
    View All 32 Advanced Conditions
    View All 63 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile